US · RNA
Avidity Biosciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92121
- Website
- aviditybiosciences.com
Price · as of 2025-12-31
$13.43
Market cap 2.28B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $21.71 | +61.65% |
| Intrinsic Value(DCF) | $9.65 | -28.15% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $3.90 | $0.00 | |||
| 2021 | $0.00 | $0.00 | |||
| 2022 | $0.00 | $0.00 | |||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $0.00 | $0.00 | |||
| 2025 | $14.91 | $21.71 | $6.29 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Avidity Biosciences, Inc.'s (RNA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $21.71
- Current price
- $13.43
- AI upside
- +61.65%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$9.65
-28.15% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RNA | Avidity Biosciences, Inc. | $13.43 | 2.28B | +62% | -28% | — | — | -3.00 | 1.22 | 109.48 | -0.66 | -4.17 | 1.22 | 77.87% | -3977.30% | -3650.39% | -43.98% | -9010.06% | -38.88% | 0.06 | — | 9.20 | 8.75 | 0.42 | 7197.00% | 7211.00% | 11555.00% | -32.33% | -3.33 | -8017.39% | 0.00% | 0.00% | 3.65% | -0.60 | -0.68 | 24.04 | 3.18 |
| ABVX | Abivax S.A. | $121.28 | 7.95B | -67% | -97% | — | — | -2.42 | 10.50 | 39.48 | -2.21 | — | 27.39 | 100.00% | -1602.89% | -1633.08% | -148.98% | 2618.19% | -66.22% | 2.40 | -41.33 | 1.84 | 1.72 | 0.27 | -1837.00% | 13354.00% | 5429.00% | -36.31% | -1.66 | 2341.68% | 0.00% | 0.00% | 0.00% | -2.19 | -2.45 | 35.14 | -3.71 |
| CAI | Caris Life Sciences, Inc. | $20.14 | 5.68B | +132% | +659% | — | — | -507.35 | 59.84 | 42.54 | 2965.27 | — | 61.91 | 66.40% | 5.56% | -66.25% | 7.09% | -3.82% | -9.27% | 0.00 | 0.79 | 7.85 | 7.17 | -70.09 | -2963.00% | 9697.00% | -12637.00% | 0.19% | 0.65 | -5.66% | 0.00% | 0.00% | 3.35% | 748.01 | 504.44 | 41.56 | 36.41 |
| CYTK | Cytokinetics, Incorporate… | $62.22 | 7.61B | -4% | -61% | — | — | -9.39 | -11.18 | 83.75 | -10.03 | -38.60 | -11.18 | 100.00% | -695.44% | -891.60% | 197.47% | 179.99% | -55.55% | -1.95 | — | 4.53 | 4.36 | -0.52 | 2433.00% | 37656.00% | 3377.00% | -7.25% | -2.52 | 157.23% | 0.00% | 0.00% | 3.96% | -12.70 | -14.54 | 88.31 | -2.06 |
| JAZZ | Jazz Pharmaceuticals plc | $190.02 | 11.7B | -5% | -56% | -94% | — | -32.61 | 2.69 | 2.72 | 104.22 | — | -5.99 | 88.21% | 5.26% | -8.35% | -8.47% | 2.26% | -3.01% | 0.25 | 1.15 | 1.86 | 0.99 | -2.87 | -16751.00% | 488.00% | -377.00% | 11.17% | 0.60 | 23.02% | 0.00% | 0.00% | 36.04% | 50.37 | 8.72 | 2.65 | 1.65 |
| MDGL | Madrigal Pharmaceuticals,… | $432.00 | 9.81B | -42% | +134,896% | — | — | -33.90 | 16.22 | 10.20 | -34.57 | — | 16.42 | 94.14% | -31.31% | -30.08% | -42.49% | 761.60% | -25.05% | 0.59 | -13.45 | 4.01 | 3.60 | -0.59 | -4132.00% | 43205.00% | -5842.00% | -1.94% | -0.61 | 482.24% | 0.00% | 0.00% | 0.00% | -30.47 | -48.12 | 9.54 | 7.47 |
| MRNA | Moderna, Inc. | $53.57 | 20.93B | -39% | -52% | — | +298% | -7.28 | 2.38 | 10.57 | -6.53 | — | 2.38 | 55.35% | -158.13% | -145.16% | -28.87% | -65.47% | -21.31% | 0.22 | — | 3.29 | 3.01 | 0.27 | -2168.00% | -3923.00% | -4908.00% | -10.05% | -0.94 | -43.98% | 0.00% | 0.00% | 0.00% | -5.42 | -8.07 | 8.58 | 3.94 |
| MRUS | Merus N.V. | $90.00 | 6.83B | -61% | -76% | — | -87% | -13.74 | 4.57 | 84.83 | -9.34 | -117.77 | 4.58 | 37.15% | -752.96% | -595.93% | -42.88% | -391.57% | -34.71% | 0.02 | — | 6.54 | 6.22 | 1.09 | 1167.00% | -1238.00% | 2826.00% | -6.34% | -2.13 | -279.56% | 0.00% | 0.00% | 3.06% | -9.26 | -12.97 | 69.71 | 11.12 |
| NUVL | Nuvalent, Inc. | $101.95 | 7.41B | — | — | — | — | -17.31 | 5.90 | — | -571.33 | -35.43 | 5.90 | 0.00% | — | — | -36.70% | 481.41% | -33.30% | 0.00 | — | 15.27 | 15.05 | 24.96 | 4885.00% | — | 4871.00% | -3.74% | -3.02 | 319.78% | 0.00% | 0.00% | 1.58% | -14.46 | -21.77 | — | 26.05 |
| RYTM | Rhythm Pharmaceuticals, I… | $92.73 | 6.19B | -37% | +215% | — | — | -31.39 | 44.36 | 32.51 | -33.22 | — | 46.13 | 89.73% | -101.19% | -106.41% | -129.46% | 96.50% | -45.05% | 0.03 | -9.33 | 4.41 | 3.92 | 0.29 | -2834.00% | 4583.00% | 241.00% | -1.89% | -1.09 | 58.61% | 0.09% | -2.70% | 0.09% | -30.13 | -49.60 | 30.48 | 13.65 |
| TECH | Bio-Techne Corporation | $59.00 | 9.23B | -19% | -63% | -94% | -90% | 116.45 | 4.45 | 7.01 | 40.71 | — | 14.94 | 64.80% | 8.38% | 6.02% | 3.68% | 3.36% | 2.79% | 0.23 | 12.02 | 3.46 | 2.10 | 1.30 | -5619.00% | 523.00% | 866.00% | 3.00% | 1.64 | 11.31% | 0.59% | 68.70% | 3.82% | 86.35 | 34.42 | 7.24 | 9.42 |
About Avidity Biosciences, Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
- CEO
- Sarah Boyce
- Employees
- 391
- Beta
- 0.93
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9.65 ÷ $13.43) − 1 = -28.15% (DCF, example).